GCM
ALLO icon

Graham Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Graham Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
43,264
-105,407
-71% -$211K ﹤0.01% 1035
2025
Q4 		$204K Sell
148,671
-48,637
-25% -$64.2K ﹤0.01% 1036
2025
Q3 		$245K Sell
197,308
-104,962
-35% -$125K ﹤0.01% 958
2025
Q2 		$342K Buy
+302,270
New +$402K 0.01% 949
2025
Q1 		– Sell
-41,737
Closed -$88.9K – 1269
2024
Q4 		$88.9K Buy
+41,737
New +$103K ﹤0.01% 1167
2023
Q3 		– Sell
-62,431
Closed -$310K – 997
2023
Q2 		$310K Buy
62,431
+41,525
+199% +$225K 0.01% 673
2023
Q1 		$103K Buy
+20,906
New +$134K ﹤0.01% 1001
2022
Q4 		– Sell
-103,895
Closed -$1.12M – 1030
2022
Q3 		$1.12M Sell
103,895
-130,975
-56% -$1.78M 0.04% 435
2022
Q2 		$2.68M Buy
234,870
+91,040
+63% +$808K 0.11% 134
2022
Q1 		$1.31M Buy
+143,830
New +$1.5M 0.05% 216

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's ALLO Position: Q1 2026 in Review

Graham Capital Management reduced its Allogene Therapeutics (ALLO) stake by 71% in Q1 2026, selling an estimated $211K and leaving 43,264 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Graham Capital Management first reported a position in ALLO in Q1 2022 and has held it in 10 quarters since. The position peaked at $2.68M in Q2 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Graham Capital Management held 43,264 shares of Allogene Therapeutics worth $106K as of Q1 2026.
  • Graham Capital Management sold 105,407 Allogene Therapeutics shares in Q1 2026, an estimated $211K.
  • Allogene Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1035 holding.
  • Graham Capital Management first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Graham Capital Management's Allogene Therapeutics position peaked at $2.68M in Q2 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.